Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features

Peng,Jie; Valeshabad,Ali Kord; Li,Qingfu; Wang,Yuan

doi:10.3892/ol.2012.1080

Differential expression of RBM5 and KRAS in pancreatic ductal adenocarcinoma and their association with clinicopathological features

Authors:
- Jie Peng
- Ali Kord Valeshabad
- Qingfu Li
- Yuan Wang
View Affiliations

Affiliations: Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P.R. China, Department of Medicine and Division of Gastroenterology and Hepatology, The John Hopkins Medical Institutions, Baltimore, MD, USA
Published online on: December 17, 2012 https://doi.org/10.3892/ol.2012.1080
Pages: 1000-1004

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

RNA binding motif 5 (RBM5) is a tumor suppressor gene that regulates cell proliferation, differentiation and apoptosis through pre-mRNA splicing of related genes. This study aimed to detect RBM5 and KRAS expression in pancreatic ductal adenocarcinoma and their association with clinicopathological features. Detection of RBM5 and KRAS expression by quantitative reverse transcription-polymerase chain reaction (qRT-PCR) and western blotting was performed at mRNA and protein levels, respectively, in pancreatic cancer and non-tumor tissues. In addition, the association of RBM5 and KRAS expression with clinicopathological parameters and tumor recurrence was analyzed. The expression of RBM5 was significantly downregulated in pancreatic cancer tissues compared to peritumoral tissues at the mRNA and protein levels. Contrastingly, KRAS was significantly overexpressed in pancreatic cancerous tissues compared to peritumoral tissues. Analysis revealed that RBM5 expression was negatively correlated with KRAS expression in pancreatic cancer. Furthermore, reduced RBM5 expression has a close association with lymph node metastasis, distant metastasis, Union for International Cancer Control (UICC) stage and nerve and venous invasion, while overexpression of KRAS proteins was significantly correlated with tumor size, lymph node metastasis, UICC stage and nerve and venous invasion of pancreatic cancer. Significant RBM5 underexpression and KRAS overexpression were observed in pancreatic cancer compared to non-tumor tissues. There is a close association of differential RBM5 and KRAS with poor clinicopathological features, suggesting their potential roles in the progression and metastasis of pancreatic cancer.

View Figures

View References

1	Warshaw AL and Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med. 326:455–465. 1992. View Article : Google Scholar : PubMed/NCBI
2	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar
3	Yeo TP, Hruban RH, Leach SD, et al: Pancreatic cancer. Curr Probl Cancer. 26:176–275. 2002. View Article : Google Scholar : PubMed/NCBI
4	Sutherland LC, Wang K and Robinson AG: RBM5 as a putative tumor suppressor gene for lung cancer. J Thorac Oncol. 5:294–298. 2010. View Article : Google Scholar : PubMed/NCBI
5	Oh JJ, Razfar A, Delgado I, et al: 3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis. Cancer Res. 66:3419–3427. 2006. View Article : Google Scholar : PubMed/NCBI
6	Heidorn SJ, Milagre C, Whittaker S, et al: Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell. 140:209–221. 2010. View Article : Google Scholar : PubMed/NCBI
7	Suda K, Tomizawa K and Mitsudomi T: Biological and clinical significance of KRAS mutations in lung cancer: an oncogenic driver that contrasts with EGFR mutation. Cancer Metastasis Rev. 29:49–60. 2010. View Article : Google Scholar : PubMed/NCBI
8	Schneider G and Schmid RM: Genetic alterations in pancreatic carcinoma. Mol Cancer. 2:152003. View Article : Google Scholar
9	Kobayashi T, Ishida J, Musashi M, et al: p53 transactivation is involved in the antiproliferative activity of the putative tumor suppressor RBM5. Int J Cancer. 128:304–318. 2011. View Article : Google Scholar : PubMed/NCBI
10	Liang H, Zhang J, Shao C, et al: Differential expression of RBM5, EGFR and KRAS mRNA and protein in non-small cell lung cancer tissues. J Exp Clin Cancer Res. 31:362012. View Article : Google Scholar : PubMed/NCBI
11	Sobin LH and Fleming ID: TNM Classification of Malignant Tumors. Vol 80 (5th edition). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. 1803–1804. 1997.
12	Zhou X, Hao Q, Liao J, Zhang Q and Lu H: Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene. 2012.PubMed/NCBI
13	Rintala-Maki ND, Goard CA, Langdon CE, et al: Expression of RBM5-related factors in primary breast tissue. J Cell Biochem. 100:1440–1458. 2007. View Article : Google Scholar : PubMed/NCBI
14	Welling DB, Lasak JM, Akhmametyeva E, Ghaheri B and Chang LS: cDNA microarray analysis of vestibular schwannomas. Otol Neurotol. 23:736–748. 2002. View Article : Google Scholar : PubMed/NCBI
15	Kim YS, Hwan JD, Bae S, Bae DH and Shick WA: Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC Cancer. 10:5762010. View Article : Google Scholar : PubMed/NCBI
16	Maarabouni MM and Williams GT: The antiapoptotic RBM5/LUCA-15/H37 gene and its role in apoptosis and human cancer: research update. Scientific World Journal. 6:1705–1712. 2006. View Article : Google Scholar : PubMed/NCBI
17	Rintala-Maki ND, Abrasonis V, Burd M and Sutherland LC: Genetic instability of RBM5/LUCA-15/H37 in MCF-7 breast carcinoma sublines may affect susceptibility to apoptosis. Cell Biochem Funct. 22:307–313. 2004. View Article : Google Scholar : PubMed/NCBI
18	Shao C, Zhao L, Wang K, Xu W, Zhang J and Yang B: The tumor suppressor gene RBM5 inhibits lung adenocarcinoma cell growth and induces apoptosis. World J Surg Oncol. 10:1602012. View Article : Google Scholar : PubMed/NCBI
19	Oh JJ, Taschereau EO, Koegel AK, et al: RBM5/H37 tumor suppressor, located at the lung cancer hot spot 3p21.3, alters expression of genes involved in metastasis. Lung Cancer. 70:253–262. 2010. View Article : Google Scholar : PubMed/NCBI
20	Wang K, Ubriaco G and Sutherland LC: RBM6-RBM5 transcription-induced chimeras are differentially expressed in tumours. BMC Genomics. 8:3482007. View Article : Google Scholar : PubMed/NCBI
21	Kang R and Tang D: Autophagy in pancreatic cancer pathogenesis and treatment. Am J Cancer Res. 2:383–396. 2012.PubMed/NCBI
22	Ying H, Kimmelman AC, Lyssiotis CA, et al: Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell. 149:656–670. 2012. View Article : Google Scholar : PubMed/NCBI
23	Rall CJ, Yan YX, Graeme-Cook F, et al: Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Pancreas. 12:10–17. 1996. View Article : Google Scholar : PubMed/NCBI
24	Hruban RH, van Mansfeld AD, Offerhaus GJ, et al: K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol. 143:545–554. 1993.
25	Grunewald K, Lyons J, Frohlich A, et al: High frequency of Ki-ras codon 12 mutations in pancreatic adenocarcinomas. Int J Cancer. 43:1037–1041. 1989. View Article : Google Scholar : PubMed/NCBI
26	Garcea G, Neal CP, Pattenden CJ, Steward WP and Berry DP: Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 41:2213–2236. 2005. View Article : Google Scholar : PubMed/NCBI
27	Castells A, Puig P, Mora J, et al: K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J Clin Oncol. 17:578–584. 1999.PubMed/NCBI
28	Finkelstein SD, Przygodzki R, Pricolo VE, et al: K-ras-2 topographic genotyping of pancreatic adenocarcinoma. Arch Surg. 129:367–372; discussion 372–363, 1994.
29	Gazdar AF, Gao B and Minna JD: Lung cancer cell lines: Useless artifacts or invaluable tools for medical science? Lung Cancer. 68:309–318. 2010. View Article : Google Scholar : PubMed/NCBI
30	Masilamani TJ, Rintala-Maki ND, Wang K and Sutherland LC: Downregulating activated epidermal growth factor receptor has no effect on RBM5 expression. Chin Med J (Engl). 125:2378–2381. 2012.PubMed/NCBI
31	Song MM, Nio Y, Dong M, et al: Comparison of K-ras point mutations at codon 12 and p21 expression in pancreatic cancer between Japanese and Chinese patients. J Surg Oncol. 75:176–185. 2000. View Article : Google Scholar : PubMed/NCBI
32	Dergham ST, Dugan MC, Kucway R, et al: Prevalence and clinical significance of combined K-ras mutation and p53 aberration in pancreatic adenocarcinoma. Int J Pancreatol. 21:127–143. 1997.PubMed/NCBI
33	Motojima K, Urano T, Nagata Y, Shiku H, Tsunoda T and Kanematsu T: Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinoma. Am J Gastroenterol. 86:1784–1788. 1991.PubMed/NCBI